Company to host conference call today at 8:30am ET

London, March 21, 2023 – Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases, today announced regulatory feedback following recent end-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) related to its alvelestat program for the treatment of alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD). Company to host conference call today at 8:30am ET. 

Mereo BioPharma will hold a conference call today, March 21, at 8:30am ET. To participate by telephone, please dial (877) 418-5268 in the U.S., or (412) 902-6771 internationally, and ask for the Mereo BioPharma Group Conference Call. Alternatively you can access via http://www.wsw.com/webcast/cc/mph.l4